Featured Articles

  1. Biotech Playbook Breakdown: Who Will Risk Developing Tomorrow's Cures? 8/11/2026

    Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate earlier to bring cures to patients.

  2. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  3. Big Pharma Can't Merge Its Way Out Of An Innovation Problem 8/6/2026

    Mega-mergers may cut costs, but they won’t fix pharma’s innovation gap. Breakthroughs come through biotech partnerships, writes Sofinnova’s Jim Healy, M.D., Ph.D.

  4. Why Life Sciences Demand Venture Formation Over Venture Capital 8/3/2026

    The life sciences industry needs venture formation, not traditional VC, to turn academic breakthroughs into successful startups, writes William Garner, M.D.

  5. When AI Changes A Deal: Rethinking Risk, Milestones, And Timing In Life Sciences M&A 7/29/2026

    AI is shifting life sciences M&A risk from early milestones to later validation, reshaping valuation, diligence, and deal timing, according to experts at Sidley. 

  6. Bridging The Gap: The Contract-To-Ledger Divide In Life Sciences 7/23/2026

    Contract wording in life sciences deals can materially affect revenue recognition, metrics, and disclosures, making early legal-accounting review essential.

  7. Rebuilding the Innovation Engine: How We Got Here And What Comes Next 7/20/2026

    Federal investment in basic science built America’s innovation engine, but declining support is threatening U.S. leadership, writes Dietrich Stephan, Ph.D.

  8. Psychedelics EO May De-Risk Innovation, But Data Is Still King 7/15/2026

    A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models and rigorous data collection remain critical.

  9. Why Breakthrough Research Sits On The Shelf, And What To Do About It 7/13/2026

    Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust, and sustainable funding.

  10. Godzilla Vs. The Life Sciences Supply Chain 7/8/2026

    A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, scenario planning, and climate resilience.